SIMCERE PHARMACEUTICAL GROUP
Founded in 1995 with a vision to establish a company that would in turn help create a healthier China, Simcere Pharmaceutical Group has become a leading manufacturer and supplier of drugs in the rapidly growing China pharmaceutical market, we now have seven certified Good Manufacturing Practices ("GMP") manufacturing facilities and three research and development center and over 4,000 employees. Now Simcere has more than 20 Innovative Pharmaceuticals which are under development, and they all have independent intellectual property rights. In 2010, From them we submited five clinical trial applications to the SFDA. In 2007 Simcere successfully landed the New York Stock Exchange (ticker symbol SCR) as the first one in mainland China's chemical and biological drugs NYSE-listed company. Simcere is actively increasing our collaborations with international companies (such as Bristol-Myers Squibb Company) to develop new drugs. August 2011, Simcere signed a cooperation framework agreement with Merck to establish a company, provide patients with more high-quality drugs. Simcere has more than 20 kinds of bulk drug products have passed the GMP certification. Their preparations are saled in China for many years. The raw materials and preparations of Montmorillonite both successfully passed and received EU GMP certification. Simcere API's advantage comes from good quality. We have a very strict and continuous improvement of the quality management system. This effectively ensures verification from production equipment, raw materials, processing, semi-finished and finished product to ensure stable production process and quality. Simcere is committed to providing our customers with excellent quality products, simple and efficient service, and Simcere has been concerned with environmental, health and safety issues. We are looking forward to become a trusty cooperator in the pharmaceutical industry.
|Sales markets||Western Europe; Eastern Europe; Middle East; Asia; Australia; North America; Africa; Central/South America|
|Affiliated categories:||APIs More|
CPhI Japan 201918 - 20 March 2019 Tokyo, Japan We were at stand 3B-34 See our Exhibitor Profile See full Exhibitor List
CPhI South East Asia 201912-14 March 2019 Bangkok, Thailand We were at stand A2 See our Exhibitor Profile See full Exhibitor List
Our Top products
Aldioxa is a condensation product of allantoin and aluminum hydroxide. Its formula is C3H7AIN4O5. It is present in multi-ingredient preparations intended for treating gastric and duodenal ulcers, chronic gastritis, gastric inflammation, drug-induced gastritis. It c...
Amlodipine Maleate (GMP)
Amlodipine Maleate is a calcium channel blocking agent,and It is effective in the treatment of angina pectoris and hypertension. It inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes. The decreas...
Biapenem is a new parenteral carbapenem antibacterial agent with a broad spectrum of in vitro antibacterial activity encompassing many Gram-negative and Gram-positive aerobic and anaerobic bacteria, including species producing ß-lactamases. It was approved in Ja...
Categories affiliated with SIMCERE PHARMACEUTICAL GROUP
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation